<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158249</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-19238-1</org_study_id>
    <secondary_id>R01DA019238</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <secondary_id>R01DA024007</secondary_id>
    <nct_id>NCT00158249</nct_id>
  </id_info>
  <brief_title>Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals</brief_title>
  <official_title>Cannabis Dependence: Imaging and Medication Development - 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Three Aims of this study are (only studies for Aim 1 were completed)

        1. Measure the impact of citicoline on marihuana use patterns in subjects' individualized
           natural settings and responses to marihuana challenge using functional brain MRI scans.

           Hypothesis - 2 g/day citicoline will produce greater reductions in marihuana use and
           craving in heavy marihuana users than placebo citicoline over a 8-week treatment period
           as measured in their natural environments. The same participants will experience greater
           improved brain activation patterns and an improvement in cognitive functioning compared
           to placebo controlled subjects.

        2. Measure the effects of citicoline on marihuana absorption and metabolism and determine
           if these changes parallel changes in subjective and physiological responses in a
           laboratory setting.

           Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will produce increases
           in subjective and physiological effects of both acute marihuana smoking and placebo
           marihuana smoking compared to chronic placebo citicoline. Citicoline will have no effect
           on marihuana pharmacokinetics.

        3. Measure the effects of citicoline on marijuana-induced cue-induced craving and brain
           electrical activity (EEG).

      Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will reduce objective
      measures of marijuana cue-reactivity, and subjective reports of craving in response to
      marihuana cues will also be attenuated compared to chronic placebo citicoline treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marijuana dependence is an important public health problem in the United States, yet still no
      effective therapies are available. It is unclear how marijuana affects brain function after
      acute or chronic use. Knowing about the changes in brain function during marijuana dependence
      would aid in the understanding of the neurobiological basis of marijuana abuse and serve as a
      foundation for the development of new treatment medications for this disorder. New and
      improved brain imaging techniques, such as functional MRI (fMRI) and magnetic resonance
      spectroscopy (MRS), allow the viewing of these subtle, yet important, changes in brain
      function.

      Citicoline is used to treat victims of head trauma and neurodegenerative disorders. It has
      been found to be effective in reducing cocaine use and craving, and it has no known side
      effects. It has also been shown to reduce marijuana use. This is likely due to citicoline's
      ability to reduce insomnia and craving, act as a mild antidepressant, and improve cognitive
      function. How citicoline reduces drug use may be related to effects on cerebral blood flow
      and/or brain phospholipid metabolism in the reward areas of the brain.

      This study will determine whether citicoline alters marijuana use patterns, reduces craving,
      and affects brain phospholipids and metabolism in marijuana-dependent people. The outcome of
      the study could offer important insights into the pathophysiology and course of marijuana
      dependence. Furthermore, this study's outcome could potentially relate to other drug
      dependence disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana Use</measure>
    <time_frame>Measured for 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Function</measure>
    <time_frame>Before and after 8 weeks of treatment</time_frame>
    <description>Multiple Source Interference Test (MSIT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>citicoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 gm/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citicoline</intervention_name>
    <description>2 gm/day, 8 weeks treatment</description>
    <arm_group_label>citicoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matched for physical appearance</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for current marijuana dependence

          -  Women with a negative pregnancy test prior to study entry

          -  Heavy smoker, defined as smoking more than 10 joints per week

        Exclusion Criteria:

          -  Abnormal electrocardiogram (ECG)

          -  Medical disorder that requires prescription medication

          -  Psychiatric disorder that requires prescription medication

          -  Abnormal liver function tests

          -  Taking herbal preparations

          -  Taking any over-the-counter medications on a chronic basis

          -  Pregnancy or breast feeding

          -  Neurological, infectious, or neoplastic disease

          -  Currently seeking treatment for marijuana abuse

          -  Meets criteria for alcohol, cocaine, or opioid dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott E. Lukas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital, Department of Psychiatry</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478 9106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>October 15, 2014</results_first_submitted>
  <results_first_submitted_qc>October 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2014</results_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Scott Lukas</investigator_full_name>
    <investigator_title>Director, MIC &amp; BPRL</investigator_title>
  </responsible_party>
  <keyword>citicoline, drug abuse, marijuana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>matched capsules
placebo: matched for physical appearance</description>
        </group>
        <group group_id="P2">
          <title>Citicoline</title>
          <description>2 gm/day
citicoline: 2 gm/day, 8 weeks treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>matched capsules
placebo: matched for physical appearance</description>
        </group>
        <group group_id="B2">
          <title>Citicoline</title>
          <description>2 gm/day
citicoline: 2 gm/day, 8 weeks treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="7.2"/>
                    <measurement group_id="B2" value="27.7" spread="6.9"/>
                    <measurement group_id="B3" value="29.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marijuana Use</title>
        <time_frame>Measured for 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>matched capsules
placebo: matched for physical appearance</description>
          </group>
          <group group_id="O2">
            <title>Citicoline</title>
            <description>2 gm/day
citicoline: 2 gm/day, 8 weeks treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Marijuana Use</title>
          <units>Reported uses per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread=".71"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Function</title>
        <description>Multiple Source Interference Test (MSIT)</description>
        <time_frame>Before and after 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>matched capsules
placebo: matched for physical appearance</description>
          </group>
          <group group_id="O2">
            <title>Citicoline</title>
            <description>2 gm/day
citicoline: 2 gm/day, 8 weeks treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Function</title>
          <description>Multiple Source Interference Test (MSIT)</description>
          <units>Accuracy percent improvement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.45" spread="18.8"/>
                    <measurement group_id="O2" value="16.08" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>matched capsules
placebo: matched for physical appearance</description>
        </group>
        <group group_id="E2">
          <title>Citicoline</title>
          <description>2 gm/day
citicoline: 2 gm/day, 8 weeks treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAusea/Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott E. Lukas, Ph.D.</name_or_title>
      <organization>McLean Hospital</organization>
      <phone>617-855-2767</phone>
      <email>slukas@mclean.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

